Akinori Nishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akinori Nishikawa has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Hiroki Hosoi
Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
4 shared publications - Shogo Murata
Department of Hematology/Oncology, Wakayama Medical University, Wakayama 641-8509, Japan
4 shared publications - Takashi Sonoki
Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
4 shared publications - Toshiki Mushino
Department of Hematology/Oncology Wakayama Medical University Wakayama Japan
4 shared publications Hiroshi Akasaka
Akasaka Clinic Kobe Japan
2 shared publications- Yoshikazu Hori
Department of Hematology/Oncology, Wakayama Medical University
2 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (3)
Remote Vital Monitoring During Home Blood Transfusions in Japan Using Attendant‐Performed Vitals: A Pilot Feasibility and Safety Study
Background and Aims: Home blood transfusion is thought to be a promising solution for reducing the burden of hospital visits for elderly patients with hematologic diseases such as myelodysplastic syndrome and leukemia. However, safety concerns and reliance on nonprofessional attendants currently limit its widespread adoption in Japan. We evaluated feasibility (completion of scheduled measurement points per transfusion day) and operational safety (frequency of alerts and proportion leading to clinical actions) of intermittent vital sign monitoring with real‐time remote alerts during home blood transfusions in Japan. Methods: Five patients receiving home transfusions via Akasaka Clinic between December 2022 and February 2023 participated in the study. A digital tablet‐based system was preconfigured to connect with Bluetooth‐enabled vital sign devices (blood pressure monitor, thermometer, and pulse oximeter). Before transfusion, baseline vital signs were measured by the visiting physician; attendants then measured vitals at 15 and 60 min and at the end of transfusion. Data were automatically transmitted to physicians via the Heartline™ system. If preset thresholds were exceeded, alerts were triggered, which prompted professional medical intervention. Results: During the 30‐day trial period, red blood cell transfusions were performed 27 times (each consisting of 2 units), and platelet concentrate transfusions were performed 15 times (each consisting of 10 units). Measurement completion rates ranged from 38% to 94% (median 70% [IQR 53–88]). Alerts occurred on 12/30 days and totaled 12 alert events, corresponding to 28.6 alerts per 100 transfusions. Four of 12 alert events (33.3%) led to clinical actions (medication administration or initiation of home oxygen). Notably, intermittent measurement effectively identified clinically significant changes. Attendants, including elderly cohabitants, were able to operate the system with minimal burden. Conclusion: Intermittent, attendant‐performed vital sign monitoring with real‐time alerts enabled timely clinical responses and was feasible, even among elderly caregivers.
- 24 March 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (3)
Open AccessRemote Vital Monitoring During Home Blood Transfusions in Japan Using Attendant‐Performed Vitals: A Pilot Feasibility and Safety Study
Background and Aims: Home blood transfusion is thought to be a promising solution for reducing the burden of hospital visits for elderly patients with hematologic diseases such as myelodysplastic syndrome and leukemia. However, safety concerns and reliance on nonprofessional attendants currently limit its widespread adoption in Japan. We evaluated feasibility (completion of scheduled measurement points per transfusion day) and operational safety (frequency of alerts and proportion leading to clinical actions) of intermittent vital sign monitoring with real‐time remote alerts during home blood transfusions in Japan. Methods: Five patients receiving home transfusions via Akasaka Clinic between December 2022 and February 2023 participated in the study. A digital tablet‐based system was preconfigured to connect with Bluetooth‐enabled vital sign devices (blood pressure monitor, thermometer, and pulse oximeter). Before transfusion, baseline vital signs were measured by the visiting physician; attendants then measured vitals at 15 and 60 min and at the end of transfusion. Data were automatically transmitted to physicians via the Heartline™ system. If preset thresholds were exceeded, alerts were triggered, which prompted professional medical intervention. Results: During the 30‐day trial period, red blood cell transfusions were performed 27 times (each consisting of 2 units), and platelet concentrate transfusions were performed 15 times (each consisting of 10 units). Measurement completion rates ranged from 38% to 94% (median 70% [IQR 53–88]). Alerts occurred on 12/30 days and totaled 12 alert events, corresponding to 28.6 alerts per 100 transfusions. Four of 12 alert events (33.3%) led to clinical actions (medication administration or initiation of home oxygen). Notably, intermittent measurement effectively identified clinically significant changes. Attendants, including elderly cohabitants, were able to operate the system with minimal burden. Conclusion: Intermittent, attendant‐performed vital sign monitoring with real‐time alerts enabled timely clinical responses and was feasible, even among elderly caregivers.
- Open Access
- 1 January 2026
- Published by The Japan Society for Hematopoietic Stem Cell Transplantation in Japanese Journal of Transplantation and Cellular Therapy
- Vol. 15 (1) , 1-6
The Future of Remote Long Term Follow Up (LTFU) Using Medical Information Sharing and Personal Health Records
同種造血幹細胞移植後は慢性移植片対宿主病(GVHD)や感染症,二次がんなどの晩期合併症により生活の質(QOL)の低下や死亡のリスクを抱えるため,移植後長期フォローアップ(LTFU)が重要である。しかし,専門医の地域偏在や患者の移動負担,就学・就労等による受診中断が課題となっている。近年,情報通信技術(ICT)を活用した遠隔医療,医療情報連携(EHR),パーソナルヘルスレコード(PHR)が進展し,LTFUの補完手段としての活用が進められている。和歌山県立医科大学では,和歌山県南部患者に対し,医療情報連携システム「青洲リンク」とWeb会議を用いたD to P with D型遠隔LTFUを実施し,現地医師と連携した診療を試みている。また,PHRアプリ「NOBORI®」を活用し,検査結果等を患者端末に蓄積・提示することで,D to P型遠隔LTFUの情報不足を補う可能性を検討している。今後は診療報酬や情報共有基盤整備,PHR推進により質の高いLTFU体制の構築が期待される。
- 1 January 2026
- Published by The Japan Society for Hematopoietic Stem Cell Transplantation in Japanese Journal of Transplantation and Cellular Therapy
- Vol. 15 (1) , 1-6
Open AccessThe Future of Remote Long Term Follow Up (LTFU) Using Medical Information Sharing and Personal Health Records
同種造血幹細胞移植後は慢性移植片対宿主病(GVHD)や感染症,二次がんなどの晩期合併症により生活の質(QOL)の低下や死亡のリスクを抱えるため,移植後長期フォローアップ(LTFU)が重要である。しかし,専門医の地域偏在や患者の移動負担,就学・就労等による受診中断が課題となっている。近年,情報通信技術(ICT)を活用した遠隔医療,医療情報連携(EHR),パーソナルヘルスレコード(PHR)が進展し,LTFUの補完手段としての活用が進められている。和歌山県立医科大学では,和歌山県南部患者に対し,医療情報連携システム「青洲リンク」とWeb会議を用いたD to P with D型遠隔LTFUを実施し,現地医師と連携した診療を試みている。また,PHRアプリ「NOBORI®」を活用し,検査結果等を患者端末に蓄積・提示することで,D to P型遠隔LTFUの情報不足を補う可能性を検討している。今後は診療報酬や情報共有基盤整備,PHR推進により質の高いLTFU体制の構築が期待される。
- Open Access
- 14 October 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (20) , 2285
Flower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
Background: Flower-shaped nuclei in plasma cells are rare in multiple myeloma. Case presentation: We report on an 88-year-old male who presented with a mass lesion in the clavicular region. A biopsy of the mass revealed an increase in mature plasma cells with round nuclei. In contrast, a bone marrow examination showed increased plasma cells with flower-shaped nuclei. The patient tested negative for human T-lymphotropic virus type-1 and was diagnosed with multiple myeloma. Conclusions: While multiple myeloma is known for intra-tumor heterogeneity, reports of morphological heterogeneity based on the site of tumor sampling are limited. In this case, the presence of plasma cells with flower-shaped nuclei enabled the identification of site-dependent morphological tumor heterogeneity.
- 14 October 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (20) , 2285
Open AccessFlower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
Background: Flower-shaped nuclei in plasma cells are rare in multiple myeloma. Case presentation: We report on an 88-year-old male who presented with a mass lesion in the clavicular region. A biopsy of the mass revealed an increase in mature plasma cells with round nuclei. In contrast, a bone marrow examination showed increased plasma cells with flower-shaped nuclei. The patient tested negative for human T-lymphotropic virus type-1 and was diagnosed with multiple myeloma. Conclusions: While multiple myeloma is known for intra-tumor heterogeneity, reports of morphological heterogeneity based on the site of tumor sampling are limited. In this case, the presence of plasma cells with flower-shaped nuclei enabled the identification of site-dependent morphological tumor heterogeneity.
- Open Access
- 4 October 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (4) , 612-623
Utilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy
Background: Although the prognosis of follicular lymphoma (FL) has improved, some patients experience early disease progression, including progression of disease within 24 months (POD24). Histological transformation is a critical event in FL. However, the heterogeneity of FL tumors makes it challenging to diagnose transformation accurately. We retrospectively applied the clinical transformation criteria used for FL transformation assessments at relapse or disease progression to conduct transformation assessments before the initial immunochemotherapy. Methods: Sixty-six FL patients who first received immunochemotherapy between January 2009 and February 2023 at our institution were selected. Twenty-three were clinical-transformation-positive (CLT+). Results: The progression-free survival (PFS) rate of the CLT+ patients was significantly lower than that of the clinical-transformation-negative (CLT−) patients. In the POD24 assessment subgroup, the CLT+ patients had a higher incidence of POD24 than the CLT− patients. There was no significant difference in PFS between the patients treated with CHOP-like regimens and those treated with bendamustine regimens. In the CHOP-like group, the CLT+ patients exhibited significantly lower PFS than the CLT− patients. In the bendamustine group, the clinical transformation did not affect PFS. Conclusion: Clinical transformation criteria may be useful for the prognostic stratification of FL prior to immunochemotherapy. Additionally, they may serve as predictors of POD24.
- 4 October 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (4) , 612-623
Open AccessUtilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy
Background: Although the prognosis of follicular lymphoma (FL) has improved, some patients experience early disease progression, including progression of disease within 24 months (POD24). Histological transformation is a critical event in FL. However, the heterogeneity of FL tumors makes it challenging to diagnose transformation accurately. We retrospectively applied the clinical transformation criteria used for FL transformation assessments at relapse or disease progression to conduct transformation assessments before the initial immunochemotherapy. Methods: Sixty-six FL patients who first received immunochemotherapy between January 2009 and February 2023 at our institution were selected. Twenty-three were clinical-transformation-positive (CLT+). Results: The progression-free survival (PFS) rate of the CLT+ patients was significantly lower than that of the clinical-transformation-negative (CLT−) patients. In the POD24 assessment subgroup, the CLT+ patients had a higher incidence of POD24 than the CLT− patients. There was no significant difference in PFS between the patients treated with CHOP-like regimens and those treated with bendamustine regimens. In the CHOP-like group, the CLT+ patients exhibited significantly lower PFS than the CLT− patients. In the bendamustine group, the clinical transformation did not affect PFS. Conclusion: Clinical transformation criteria may be useful for the prognostic stratification of FL prior to immunochemotherapy. Additionally, they may serve as predictors of POD24.
- 24 June 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (11) , 1212-1219
Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma
- 24 June 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (11) , 1212-1219
Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma
- 1 January 2023
- Vol. 64 (10) , 1280-1285
[Guillain-Barré syndrome associated with Epstein-Barr virus and cytomegalovirus reactivation during treatment for chronic graft-versus-host disease after allogeneic bone marrow transplantation].
Guillain-Barré syndrome (GBS) is a rare neurological complication of allogeneic hematopoietic stem cell transplantation (HSCT). The pathogenesis of post-HSCT GBS is unclear. Here, we report a case of GBS coincident with Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation that occurred after HSCT in a patient with myelodysplastic syndrome. A 61-year-old man was admitted to our hospital because of gait disturbance due to lower limb muscle weakness, which arose during treatment for chronic graft-versus-host disease (GVHD) five months after allogeneic HSCT. He was diagnosed with GBS based on his clinical course, cerebrospinal fluid analysis, and a nerve conduction study. At that time, he exhibited EBV and CMV reactivation. GBS improved after intravenous injection of immunoglobulins. Our case suggests that reactivation of EBV and CMV during treatment for chronic GVHD may induce GBS, and that rapidly progressive muscular weakness coincident with EBV or CMV reactivation can be a diagnostic sign of GBS after allogeneic HSCT.
- 1 January 2023
- Vol. 64 (10) , 1280-1285
[Guillain-Barré syndrome associated with Epstein-Barr virus and cytomegalovirus reactivation during treatment for chronic graft-versus-host disease after allogeneic bone marrow transplantation].
Guillain-Barré syndrome (GBS) is a rare neurological complication of allogeneic hematopoietic stem cell transplantation (HSCT). The pathogenesis of post-HSCT GBS is unclear. Here, we report a case of GBS coincident with Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation that occurred after HSCT in a patient with myelodysplastic syndrome. A 61-year-old man was admitted to our hospital because of gait disturbance due to lower limb muscle weakness, which arose during treatment for chronic graft-versus-host disease (GVHD) five months after allogeneic HSCT. He was diagnosed with GBS based on his clinical course, cerebrospinal fluid analysis, and a nerve conduction study. At that time, he exhibited EBV and CMV reactivation. GBS improved after intravenous injection of immunoglobulins. Our case suggests that reactivation of EBV and CMV during treatment for chronic GVHD may induce GBS, and that rapidly progressive muscular weakness coincident with EBV or CMV reactivation can be a diagnostic sign of GBS after allogeneic HSCT.
- Open Access
- 2 June 2022
- Published by MDPI AG in Hematology Reports
- Vol. 14 (2) , 203-209
Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report
A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). In addition to plasma exchange and corticosteroid therapy, she received rituximab therapy for inhibitor boosting but died suddenly of a cardiac arrest on day 9. The postmortem revealed microvascular platelet thrombi in multiple organs. In this case, the deterioration of the patient’s clinical status was considered to have been caused by inhibitor boosting-induced systemic microvascular occlusion. In particular, her sudden death may have been due to cardiovascular microthrombosis. Since inhibitor boosting can cause TTP patients to deteriorate rapidly, it is crucial to manage TTP patients who undergo inhibitor boosting appropriately. The monitoring of cardiac complications in TTP patients may also be essential, especially in the acute phase.
- 2 June 2022
- Published by MDPI AG in Hematology Reports
- Vol. 14 (2) , 203-209
Open AccessSudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report
A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). In addition to plasma exchange and corticosteroid therapy, she received rituximab therapy for inhibitor boosting but died suddenly of a cardiac arrest on day 9. The postmortem revealed microvascular platelet thrombi in multiple organs. In this case, the deterioration of the patient’s clinical status was considered to have been caused by inhibitor boosting-induced systemic microvascular occlusion. In particular, her sudden death may have been due to cardiovascular microthrombosis. Since inhibitor boosting can cause TTP patients to deteriorate rapidly, it is crucial to manage TTP patients who undergo inhibitor boosting appropriately. The monitoring of cardiac complications in TTP patients may also be essential, especially in the acute phase.
- Open Access
- 14 September 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (3) , e380
Remote vital signs data monitoring during home blood transfusion: A pilot study
Background and aims: Our study aimed to establish safer methods to manage home blood transfusion by using a remote vital signs data monitoring system. Home care is administered for patients with various medical disorders; however, home blood transfusion remains challenging owing to the risk of transfusion‐related complications.Methods: We set up a remote vital signs data monitoring system to improve the safety of home blood transfusions. Using an Internet‐based vital signs data monitoring system, the heart rate, electrocardiography, respiration rate, and percutaneous oxygen saturation (SpO2) were monitored and recorded during the entire home transfusion period.Results: Ten transfusions in three patients were monitored; two of the patients had an abnormality in a single vital sign (decreased SpO2 decrease and increased respiratory rate); these were not transfusion‐related complications. Vital sign anomalies also occur because of errors in using the measurement device and noise associated with body movements. The presence of abnormalities in at least two vital signs among SpO2 decrease, tachycardia, and increased respiratory rate that persisted for >5 minutes was defined as a complicated vital sign abnormality (CVSA). There were no severe transfusion‐related complications with CVSA in the present study.Conclusion: This study indicates the feasibility and sustainability of real‐time remote monitoring of vital signs for the safety of home transfusion. Although CVSA may function as an indicator of severe transfusion‐related complications, these findings need to be confirmed with further studies.
- 14 September 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (3) , e380
Open AccessRemote vital signs data monitoring during home blood transfusion: A pilot study
Background and aims: Our study aimed to establish safer methods to manage home blood transfusion by using a remote vital signs data monitoring system. Home care is administered for patients with various medical disorders; however, home blood transfusion remains challenging owing to the risk of transfusion‐related complications.Methods: We set up a remote vital signs data monitoring system to improve the safety of home blood transfusions. Using an Internet‐based vital signs data monitoring system, the heart rate, electrocardiography, respiration rate, and percutaneous oxygen saturation (SpO2) were monitored and recorded during the entire home transfusion period.Results: Ten transfusions in three patients were monitored; two of the patients had an abnormality in a single vital sign (decreased SpO2 decrease and increased respiratory rate); these were not transfusion‐related complications. Vital sign anomalies also occur because of errors in using the measurement device and noise associated with body movements. The presence of abnormalities in at least two vital signs among SpO2 decrease, tachycardia, and increased respiratory rate that persisted for >5 minutes was defined as a complicated vital sign abnormality (CVSA). There were no severe transfusion‐related complications with CVSA in the present study.Conclusion: This study indicates the feasibility and sustainability of real‐time remote monitoring of vital signs for the safety of home transfusion. Although CVSA may function as an indicator of severe transfusion‐related complications, these findings need to be confirmed with further studies.